GlassScriptPhysician profile
Robert Duke Burnham
NPI 1306803978
$1,907.48
in general payments reported to CMS, 2019-2025
24 companies · $279 in 2025
The $279 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $138 · 2021: $368 · 2022: $290 · 2023: $313 · 2024: $212 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $441.51 | 2019-2024 | Jornay Pm |
| Corium, LLC | $318.47 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $140.26 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $133.90 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $114.35 | 2019-2022 | |
| Kaleo, INC. | $85.62 | 2019-2021 | |
| Sanofi Pasteur INC. | $81.97 | 2019-2025 | |
| Pfizer INC. | $78.93 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $74.44 | 2024-2025 | Ycanth |
| Seqirus USA INC | $53.76 | 2021-2025 | Flucelvax Quadrivalent, Flucelvax |
| Tris Pharma INC | $52.30 | 2020-2024 | Dyanavel Xr |
| Cranial Technologies, INC | $49.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.72 | 2021-2025 | Gardasil 9, M-M-R II, Gardasil |
| Collegium Pharmaceutical, INC. | $37.24 | 2025 | Jornay Pm |
| Shire North American Group INC | $30.63 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $29.80 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $27.00 | 2025 | Neffy |
| Sobi, INC | $21.34 | 2021 | |
| Abbott Laboratories | $20.13 | 2025 | Id Now Instrument |
| Biomerieux INC | $19.00 | 2025 | |
| Alk-Abello, INC | $16.27 | 2025 | Neffy, Odactra, Grastek |
| Biofire Diagnostics, LLC | $15.75 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.94 | 2025 | Relexxii |
| Arbor Pharmaceuticals, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Duke Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.